Google
×
AllNewsBooksImages Maps Videos Shopping
Search tools

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES | Circulation

American Heart Association Journals
Alirocumab decreased the risk of stroke, irrespective of baseline LDL-C and history of cerebrovascular disease, over a median follow-up of 2.8 years.
58 months ago

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects

Frontiers
In 2003, clinical observations led to the discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism.
7 months ago

Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome:

American Heart Association Journals
In statin-treated patients with recent acute coronary syndrome, risk of PAD events is related to lipoprotein(a) level and is reduced by alirocumab.
54 months ago

Alirocumab Approved to Reduce Risk for Serious Cardiovascular Events

Endocrinology Advisor
The FDA has approved Praluent to reduce the risk of CV events requiring hospitalization in adults with established cardiovascular disease.
65 months ago

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

American Heart Association Journals
The US guideline criteria identify patients with recent acute coronary syndrome and dyslipidemia who are at VHR for recurrent ischemic events.
27 months ago

Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice

American Heart Association Journals
Despite data suggesting that apolipoprotein B (apoB) measurement outperforms low-density lipoprotein cholesterol level measurement in...
3 months ago